Physician profile
Rekha A John
NPI 1134113244
$511.44
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $118 · 2021: $105.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $111.32 | 2019-2021 | |
| Glaxosmithkline, LLC. | $70.37 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.30 | 2019-2021 | |
| Tris Pharma INC | $50.40 | 2020 | |
| Alexion Pharmaceuticals, INC. | $50.14 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.82 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $24.58 | 2019 | |
| Shire North American Group INC | $19.03 | 2019 | |
| Genentech USA, INC. | $15.82 | 2019 | |
| Novo Nordisk INC | $15.26 | 2020 | |
| Sobi, INC | $13.99 | 2019 | |
| Pfizer INC. | $13.62 | 2019 | |
| Kaleo, INC. | $13.62 | 2020 | |
| Qol Medical, LLC | $8.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rekha John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.